Zhou Siyuan, Liu Homgtao, Pan Zhongjie, Pan Fuqiang, Liang Qian, Qiu Houhuang, Wu Bingliang, Zhang Liming, Zhou Xiang
Department of Medical Cosmetology, Second Affiliated Hospital of Guangxi Medical University, Nanning City, Guangxi Province, China.
Guangxi Medical University, Nanning City, Guangxi Province, China.
J Cosmet Dermatol. 2025 Jun;24(6):e70253. doi: 10.1111/jocd.70253.
To evaluate the safety and efficacy of Botulinum Toxin Type A (BTX-A) injection for the treatment of tear troughs.
This study included patients with tear troughs rated as Grade 1-2 on the Barton Aesthetic Scale, who were treated between September 2023 and September 2024. These patients underwent intradermal injections of Botulinum Toxin Type A (BTX-A). Doctors conducted pre- and post-procedure assessments of the severity of tear troughs using the Barton Scale and TTRS (The Tear Trough Rating Scale). VISIA skin image analyzer (Canfield, USA) was utilized to compare the number of wrinkles, and facial scores and percentiles were calculated for objective evaluations before and after treatment. Additionally, doctors employed the Fitzpatrick Scale to assess periorbital wrinkles. This investigation was conducted as a prospective single-center study (PSS).
All 42 patients completed the study. After treatment, there was a significant improvement in VISIA-measured wrinkle count, facial scores, and percentiles. Additionally, there were significant reductions in Barton, TTRS, and Fitzpatrick scores. One case of pseudo-eyelid bags was observed post-treatment, while no other complications such as diplopia, lower eyelid skin laxity, or other adverse effects were reported.
BTX-A is effective in improving mild tear troughs while simultaneously reducing fine lines in the lower eyelid. Patients were highly satisfied with the improved appearance.
评估A型肉毒毒素（BTX-A）注射治疗泪沟的安全性和有效性。
本研究纳入了2023年9月至2024年9月期间接受治疗的、在巴顿美学量表上泪沟评分为1-2级的患者。这些患者接受了A型肉毒毒素（BTX-A）皮内注射。医生使用巴顿量表和泪沟评级量表（TTRS）对泪沟严重程度进行术前和术后评估。利用VISIA皮肤图像分析仪（美国Canfield公司）比较皱纹数量，并计算治疗前后的面部评分和百分位数以进行客观评估。此外，医生使用菲茨帕特里克量表评估眶周皱纹。本研究作为一项前瞻性单中心研究（PSS）进行。
42例患者均完成研究。治疗后，VISIA测量的皱纹数量、面部评分和百分位数有显著改善。此外，巴顿、TTRS和菲茨帕特里克评分显著降低。治疗后观察到1例假性眼袋，未报告复视、下睑皮肤松弛或其他不良反应等其他并发症。
BTX-A在改善轻度泪沟的同时，能有效减少下睑细纹。患者对外观改善高度满意。
